
Opinion|Videos|July 29, 2024
Future Treatment for Anemia of LR-MDS
Author(s)Guillermo Garcia-Manero, MD
An expert on lower-risk MDS discusses how the treatment of anemia is evolving as newer therapies enter the treatment landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What do you see as the future anemia treatment landscape for LR-MDS? What is the impact of newer therapies on the use of ESAs?
- What are the current unmet needs in the treatment of anemia in LR-MDS?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















